|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Gunma University |
|---|---|
| Information provided by: | Gunma University |
| ClinicalTrials.gov Identifier: | NCT00464282 |
Purpose
Objective: L-[3-18F]-α–methyltyrosine (FMT) is an amino-acid tracer for PET. We evaluated the diagnostic usefulness of 18F-FMT PET in non-small cell lung cancer (NSCLC) patients. Tumor uptake of 18F-FMT PET was compared with 18F-FDG PET and the correlation with L-type amino acid transporter 1 (LAT1) expression also investigated.
Method: Fifty patients with NSCLC were enrolled in this study, and a pair of PET study with 18F-FMT and 18F-FDG was performed. LAT1 expression and Ki-67 labeling index of the resected tumors were analyzed by immunohistochemical study.
| Condition |
|---|
|
Carcinoma, Non-Small-Cell Lung |
| Study Type: | Observational |
| Study Design: | Screening, Longitudinal, Defined Population, Prospective Study |
Eligibility| Ages Eligible for Study: | 8 Months to 2 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | Gunma 444 |
| Study First Received: | April 20, 2007 |
| Last Updated: | April 20, 2007 |
| ClinicalTrials.gov Identifier: | NCT00464282 History of Changes |
| Health Authority: | Japan: Institutional Review Board |
|
Fluorine–18-α–methyltyrosine, Positron emission tomography, Fluorodeoxyglucose Lung cancer, |
Amino acid transportor 1, Ki-67 Proven or suspected non-small cell lung cancer were enrolled in the study |
|
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |